If the Group is unable to commercialize ELAPRASE, VYVANSE, LIALDA, FIRAZYR, FOSRENOL (ROW) or any of its new products successfully, there may be a material adverse effect on the Group's revenues, financial condition and results of operations.
Any decrease in the combined sales of VYVANSE and ADDERALL XR will significantly reduce revenues and earnings
In 2008, the combined sales of VYVANSE and ADDERALL XR were $1,420.6 million, representing approximately 47% of the Group's total revenues. Sales of ADDERALL XR are expected to decrease significantly due to generic competition that is anticipated to commence on April 1, 2009. Any factors that decrease the sales of ADDERALL XR more significantly than expected could have a material adverse effect on the Group's financial condition and results of operations. In addition, the entrance of generic competitors for ADDERALL XR or other leading attention deficit and hyperactivity disorder ('ADHD') medications could impact the sales of VYVANSE. Other factors that could impact the sales of VYVANSE or ADDERALL XR include, but are not limited to:
- faster than anticipated erosion of ADDERALL XR sales by generic competitors; - the development and marketing of competitive pharmaceuticals to VYVANSE and ADDERALL XR; - issues impacting the production of VYVANSE or ADDERALL XR or the supply of
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved